Prognostic Scores in Non-Small-Cell Lung Cancer
Author Information
Author(s): Forrest L M, McMillan D C, McArdle C S, Angerson W J, Dunlop D J
Primary Institution: University Department of Surgery, Royal Infirmary, Glasgow
Hypothesis
Can combining C-reactive protein with other prognostic factors improve survival predictions for patients with inoperable non-small-cell lung cancer?
Conclusion
Combining C-reactive protein with traditional prognostic factors can enhance survival predictions for patients with inoperable non-small-cell lung cancer.
Supporting Evidence
- Patients with elevated C-reactive protein had significantly lower survival rates.
- Combining C-reactive protein with other factors improved survival predictions.
- Active treatment was associated with better survival outcomes.
Takeaway
Doctors can use a simple score that includes a blood test to better understand how long patients with lung cancer might live.
Methodology
The study included patients with inoperable NSCLC, collecting data on clinical stage, performance status, and blood samples for various biomarkers.
Potential Biases
Potential bias in patient selection for active treatment based on performance status.
Limitations
The study was conducted at a single center and may not be generalizable to all populations.
Participant Demographics
Majority were male, over 60 years old, with stage IV disease and varying performance statuses.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website